Study Title

Usefulness of Tumor Heterogeneity Assessment in Patients With MCRPC Undergoing Radioligand Therapy With 177LU-PSMA-617 Using Serial 18F-DCFPYL, 18F-FDG and 18F-Fluciclovine PET/CT Predicting Clinical Outcome

Study Details

Description:

The imaging analysis will consist in obtaining quantitative measurements of lesion uptake on the pre- and post-LuPSMA RLT (lesion and whole-body SUVmax, SUVmean and tumor volume) at each time point on all PET/CT scans. PET metrics at the lesion- and whole-body level will be compared among different PET radiopharmaceuticals at the same time point, and changes over time will be assessed.

Sponsor:

VA Greater Los Angeles Healthcare System

Contacts:

Gholam Berenji, MD

gholam.berenji@va.gov

310-268-3547

Janake Wijesuriya, BS

janake.wijesuriya@va.gov

310-977-5209

© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468